Mesalazine sustained-release tablets (DrugBank: Mesalazine)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02769494 (ClinicalTrials.gov) | March 2016 | 9/3/2016 | The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer | The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease | Crohn's Disease;Oral Ulcer | Drug: Mesalazine Sustained-Release Tablets;Drug: Riboflavin Sodium Phosphate Injection | Xijing Hospital of Digestive Diseases | NULL | Recruiting | 18 Years | 65 Years | Both | 40 | Phase 3 | China |